+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

miRNA Sequencing & Assay Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 194 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5454830
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The miRNA sequencing and assay market is witnessing transformative growth, driven by continuous innovation, collaborative investment, and workflow scalability. As a foundation for modern translational research and diagnostics, this evolving sector offers unique avenues for clinical and scientific advancement.

Market Snapshot: miRNA Sequencing and Assay Market Overview

The miRNA sequencing and assay market expanded from USD 380.21 million in 2024 to USD 435.69 million in 2025 and is forecasted to achieve a 14.55% CAGR, reaching USD 1.12 billion by 2032. This substantial growth reflects rising adoption of miRNA technologies for precision medicine, advanced molecular diagnostics, and the incorporation of these platforms throughout global drug development pipelines. Strategic investments in enabling solutions across leading regions highlight the market's role in advancing research and clinical applications.

Scope & Segmentation: Unlocking Industry Breadth

This research report offers comprehensive coverage of the miRNA sequencing and assay market, spanning products, technologies, applications, end users, workflows, sample types, and key geographies. Stakeholders benefit from in-depth, actionable segmentation insights that support market entry, competitive benchmarking, and strategy refinement.

  • Product Types: Expression assay kits covering microarray-based, qRT-PCR, and sequencing approaches; sequencing platforms tailored for miRNA workflows; and a wide range of services, including bioinformatics and sequencing support.
  • Technologies: Coverage of microarray analysis, next-generation sequencing, and RT-qPCR designed for robust miRNA profiling, quantification, and validation across research and clinical settings.
  • Applications: Clinical diagnostics, disease mechanism studies, and drug discovery, with miRNA panels driving translational breakthroughs and preclinical innovations for complex disease management.
  • End Users: Academic institutions, contract research organizations, hospital and diagnostic laboratories, and pharmaceutical and biotechnology companies implementing miRNA solutions in diverse workflows.
  • Workflows: Consumables such as assay kits, reagents, and laboratory plastics, alongside value-added services like advanced data analysis and tailored sequencing.
  • Sample Types: Blood, serum/plasma, and tissue specimens providing critical input for assay protocol design and consumables optimization in both discovery and diagnostic applications.
  • Regions: Market analysis includes the Americas (United States, Canada, and Latin America), Europe, Middle East & Africa (with coverage of Western/Eastern Europe and Sub-Saharan Africa), and Asia-Pacific (featuring China, India, Japan, Southeast Asia, and other rapidly developing markets).
  • Featured Companies: The report delivers detailed market trends and share analysis for Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Roche, Bio-Rad, Takara Bio, New England Biolabs, NanoString Technologies, and PerkinElmer.

Key Takeaways for Decision-Makers

  • Investment in advanced platforms for miRNA sequencing, paired with integration of AI-driven bioinformatics, is refining data analysis, which accelerates actionable research and clinical outcomes.
  • Collaborative partnerships involving academic researchers, industry leaders, and bioinformatics providers are improving translational value by enabling the rapid development of companion diagnostics and therapeutic monitoring tools.
  • The spread of flexible, cloud-enabled service models is making global collaboration more accessible, particularly for contract research organizations and academic centers expanding into new disease areas and markets.
  • The drive toward standardized workflows and robust validation protocols is enhancing regulatory acceptance and facilitating broader adoption, especially for oncology, neurology, and rare disease diagnostics.
  • Mitigation strategies such as subscription-based models and domestic reagent manufacturing are strengthening supply chain reliability and supporting consistent access to critical assay materials amid global market fluctuations.

Tariff Impact: Navigating Supply Chain Disruption in 2025

Recent tariff adjustments in the United States are prompting shifts in procurement and supply chain strategies for miRNA sequencing solutions. Supply chain stakeholders are increasing focus on vertical integration, ramping up local manufacturing, and adopting alternative reagent chemistries to address higher duties. End users are responding by consolidating suppliers and refining protocols, reducing vulnerabilities to cost variability and supply interruptions.

Methodology & Data Sources

This report is grounded in a rigorous, multi-phase research approach designed to yield reliable, executive-level intelligence. Insights stem from direct interviews with leading researchers and business executives, comprehensive reviews of peer-reviewed publications, regulatory submissions, patent filings, and detailed vendor documentation. Scenario modeling and triangulation across diverse data sources ensure robustness and transparency.

Why This Report Matters

  • Empowers leaders to benchmark operational performance against industry innovators while effectively navigating regulatory and technological shifts shaping miRNA sequencing and assay strategies.
  • Delivers a strategic foundation for identifying new growth corridors, refining product development pipelines, and making informed decisions on geographic expansion in a data-centric environment.

Conclusion

This market analysis provides senior decision-makers with actionable insights and clarity, supporting effective investments and long-term integration of miRNA sequencing and assay technologies across research and clinical landscapes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Emergence of single-cell microRNA profiling platforms enabling detailed cellular heterogeneity analysis
5.2. Integration of AI-driven bioinformatics pipelines for rapid miRNA expression data interpretation and biomarker discovery
5.3. Expansion of extracellular vesicle miRNA assay applications for non-invasive cancer diagnostics and real-time patient monitoring
5.4. Development of multiplexed digital PCR assays for absolute quantification of diverse microRNAs in clinical specimens
5.5. Rollout of automated high-throughput miRNA sequencing workflows reducing hands-on time and enhancing reproducibility
5.6. Adoption of standardized library preparation kits to minimize biases in microRNA NGS results across multiple research laboratories
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. miRNA Sequencing & Assay Market, by Product Type
8.1. Expression Assay Kit
8.1.1. Microarray Kit
8.1.2. Qrt-Pcr Kit
8.1.3. Sequencing Kit
8.2. Sequencing Platform
8.3. Services
8.3.1. Bioinformatics Services
8.3.2. Sequencing Services
9. miRNA Sequencing & Assay Market, by Technology
9.1. Microarray
9.2. Next Generation Sequencing
9.3. Rt-Qpcr
10. miRNA Sequencing & Assay Market, by Application
10.1. Clinical Diagnostics
10.2. Disease Research
10.3. Drug Discovery
11. miRNA Sequencing & Assay Market, by End User
11.1. Academic Institutions
11.2. Contract Research Organizations
11.3. Hospitals & Diagnostic Laboratories
11.4. Pharmaceutical & Biotech
12. miRNA Sequencing & Assay Market, by Workflow
12.1. Consumables
12.1.1. Kits & Reagents
12.1.2. Labware
12.2. Services
12.2.1. Data Analysis Services
12.2.2. Sequencing Services
13. miRNA Sequencing & Assay Market, by Sample Type
13.1. Blood
13.2. Serum/Plasma
13.3. Tissue
14. miRNA Sequencing & Assay Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. miRNA Sequencing & Assay Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. miRNA Sequencing & Assay Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Illumina, Inc.
17.3.2. Thermo Fisher Scientific Inc.
17.3.3. QIAGEN N.V.
17.3.4. Agilent Technologies, Inc.
17.3.5. F. Hoffmann-La Roche Ltd
17.3.6. Bio-Rad Laboratories, Inc.
17.3.7. Takara Bio Inc.
17.3.8. New England Biolabs, Inc.
17.3.9. NanoString Technologies, Inc.
17.3.10. PerkinElmer, Inc.
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this miRNA Sequencing & Assay market report include:
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Takara Bio Inc.
  • New England Biolabs, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.

Table Information